Related Experiment Videos
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
Ee Tuan Lim1, Axel Petzold, Siobhan M Leary
1Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK. e.lim@ion.ucl.ac.uk
Journal of Negative Results in Biomedicine
|October 16, 2004
Summary
Serum S100B levels do not correlate with disease progression or MRI findings in primary progressive multiple sclerosis (PPMS) patients treated with Interferon beta-1a. This study found no association between S100B and clinical outcomes in PPMS.
Area of Science:
- Neuroscience
- Biochemistry
- Immunology
Background:
- S100B is a calcium-binding protein involved in cellular regulation.
- Its role in neurodegenerative diseases like multiple sclerosis (MS) is under investigation.
- Primary progressive multiple sclerosis (PPMS) is a debilitating form of MS.
Purpose of the Study:
- To investigate the association between serum S100B levels and disability or MRI findings in PPMS.
- To determine if Interferon beta-1a treatment affects S100B levels in PPMS patients.
Main Methods:
- Utilized data from a randomized, controlled trial of Interferon beta-1a in PPMS subjects.
- Measured serial serum S100B levels using an Enzyme-Linked Immunosorbent Assay (ELISA).
Main Results:
- Serum S100B levels showed no significant relationship with disease progression in PPMS.
- No correlation was found between S100B levels and MRI findings in PPMS patients.
- Interferon beta-1a treatment did not alter S100B levels, nor did S100B correlate with outcome measures.
Conclusions:
- Serum S100B is not a reliable biomarker for disease activity or progression in PPMS patients treated with Interferon beta-1a.
- Further research is needed to explore the potential role of S100B in other MS subtypes or disease stages.